International Journal of PharmaceuticsImmunologyPeer-reviewed journal article
A Spray Dried Replicon Vaccine Platform for Pandemic Response
Wynton D. McClaryiD, John Z. CheniD, Hui WangiD, Ethan LoiD, Julie Bakken, Joseph McCollumiD, Christopher Press, Eduard H. MeliefiD, Devin S. Brandt, Andrew R. MartiniD, Reinhard VehringiD, Darshan N. KasaliD, Emily A. VoigtiD, Alana GerhardtiD
- Citations
- 2
- FWCI
- 1.38
- Field percentile
- top 20%
Abstract
The recent COVID-19 pandemic, as well as the threat of a global pandemic caused by H5N1 avian influenza virus, has highlighted the need for the development of thermostable vaccines that can be manufactured and distributed rapidly to combat the next global pandemic. To address this need, we previously developed a replicon vaccine platform that utilizes a nanostructured lipid carrier (NLC) to protect and efficiently deliver antigen-expressing replicon molecules in vivo. The replicon-NLC vaccine platform uses readily sourced components and can be rapidly manufactured at scale with the potential for stockpiling, thus enhancing pandemic preparedness. Spray drying is a promising method of vaccine desiccation with reduced costs and increased scale-up capabilities compared to lyophilization. As proof of concept, we demonstrate for the first time the successful spray drying of a replicon-NLC vaccine complex designed to protect against H5N1 avian influenza A virus to enhance its long-term thermostability while maintaining vaccine immunogenicity in an in vivo mouse model. Several glass-forming disaccharide excipients were screened for formulation and process compatibility under low-temperature spray drying conditions, and it was determined that a suitable shell-forming excipient, L-leucine, was necessary to prevent excessive accumulation of replicon-NLC vaccine complexes on the dry powder surface and a subsequent loss in process yield. The spray dried replicon-NLC vaccine powders were chemically stable for 1 month of storage at 40{degrees}C. Immunogenicity of the spray dried drug product was also well maintained for at least 3 months of storage at 4{degrees}C when administered intramuscularly into C57BL/6 mice as a reconstituted liquid. Finally, we demonstrate the ability to precisely control the aerodynamic particle size of the spray dried vaccine product to generate dry powders that are theoretically suitable for nasal or pulmonary delivery without reconstitution. This work establishes the feasibility of spray drying a thermostable replicon-NLC vaccine for rapid pandemic response.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Development of an Intranasally- and Intramuscularly-Administrable Replicon Vaccine Efficacious Against H5N1 Influenza Virus
Wynton D. McClary, Devin S. Brandt, … Emily A. Voigt·bioRxiv·Mar 31, 2025
- A Thermostable, Flexible RNA Vaccine Delivery Platform for Pandemic Response
A. Gerhardt, E. Voigt, … C. Casper·bioRxiv·Feb 1, 2021
- Lyophilized mRNA-lipid nanoparticle vaccines with long-term stability and high antigenicity against SARS-CoV-2
- Immunogenicity of an AAV-based, room-temperature stable, single dose COVID-19 vaccine in mice and non-human primates
N. Zabaleta, W. Dai, … L. H. Vandenberghe·bioRxiv·Jan 5, 2021
- An intranasal, NLC-delivered self-amplifying RNA vaccine establishes protective immunity against pre-pandemic H5N1 and H7N9 influenza
Matthew Ykema, Michael A. Davis, … Emily A. Voigt·bioRxiv·Jan 7, 2025
- A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability
E. A. Voigt, A. Gerhardt, … C. Casper·bioRxiv·Mar 22, 2022